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IMPLANTED PACEMAKER 
REGARDING TO COMPLETE 
ATRIOVENTRICULAR BLOCK : 
A CASE REPORT 
INTRODUCTION  
• Complete atrioventricular (AV) block due to slowing or stopping the 
passing of the electric impulse between atriums and ventricles is life-
threatening and leads to disorders of the heart rhythm and 
hemodynamic dysfunctions 1 
• Implantation of the pacemaker is widely used and has a positive 
clinical effect in patients with hemodynamically significant 
bradyarrhythmias and chronic heart failure (CHF), but it is the only 
method for treating complete AV block 2 
 
________________________ 
1 https://emedicine.medscape.com/article/151597-overview#showall 
2 https://emedicine.medscape.com/article/162007-treatment  
 
RECOMENDAIONS FOR PACEMAKER 
IMPLANATION 3 
 Class I 
 1. Complete AV block at any anatomic level associated with any one of the following conditions: 
  a. Bradycardia with symptoms presumed to be due to AV block. (Level of evidence: C) 
  b. Arrhythmias and other medical conditions that require drugs that result in symptomatic conditions. 
(Level of evidence: C) 
  c. Documented periods of asystole ≥3.0 seconds or any escape rate <40 beats per minute (bpm) in 
awake, symptom-free patients. (Level of evidence: B, C) 
  d. After catheter ablation of the AV junction. (Level of evidence: B, C) There are no trials to assess 
outcome without pacing, and pacing is virtually always planned in this situation unless the operative 
procedure is AV junction modification. 
  e. Postoperative AV block that is not expected to resolve. (Level of evidence: C) 
  f. Neuromuscular diseases with AV block such as myotonic muscular dystrophy, Kearns-Sayre 
syndrome, Erb’s dystrophy (limb-girdle), and peroneal muscular atrophy. (Level of evidence: B) 
_______________________________ 
  3 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy / [M. Brignole, A. Auricchio, B. Gonzalo et.al.]. // European Heart Journal. – 2013. 
 
PACEMAKER INSERTION 
https://www.nhlbi.nih.gov/health/health-topics/topics/pace/howdoes 
https://steptohealth.ru/micra-samyj-malenkij-v-mire-kardiostimulyator-kotoryj-mozhno-ustanovit-bez-hirurgicheskogo-vmeshatelstva/  
 
 
MAIN TYPES OF PACEMAKERS 
• Single chamber pacing mode 
• VVI (R) - Atrial fibrillation 
• Dual chambers pacing mode 
• DDD (R) - Sinus mode dysfunction, AV blocks, need for rate responsiveness 
• Three chambers pacing mode 
• CRT (P/D) – Chronic heart failure with QRS > 150 mc, EF < 35%. 
 
CLINICAL CASE 
PASSPORT DATA 
• Name: L 
• Age: 46 
• Female 
• Marital Status: Married 
• Address: Kharkov, Ukraine 
• Occupation: Traffic Warder 
• Date of admission to the hospital: 06/09/2017 
 
 
MAIN COMPLAINTS 
• General weakness, dizziness 
• Presyncope  
• Shortness of breath during physical activity (walking), disappearing 
after the rest 
• Light palpitation 
• Headaches in the occipital, parietal, frontal area, pressing character, 
periodic, arising during excitement, physical exertion 
 
HISTORY OF PRESENT ILLNESS 1.1  
• Main complaints were felt 1 month ago 
• Last exacerbation was 1 day ago, she didn’t take any drugs 
• After consulting with the physician and ECG monitoring complete AV 
block was founded ➡️ patient was admitted to the hospital 
(07.09.2017) for further observation and tests 
HISTORY OF PRESENT ILLNESS 1.2 
ECG X/X/2016 
 
 
 
 
 
 
 
Conclusion: AV block second degree (Mobitz II) 2:1, heart rate 68 bpm, 
atrial rhythm regular, ventricular rhythm irregular, PR interval prolonged  
 
HISTORY OF PRESENT ILLNESS 1.3 
ECG 07/09/2017. Complains: dizziness, weakness, presyncope  
 
 
 
 
 
 
 
Conclusion: complete AV block, heart rate 35 bpm, sinus atrial rhythm, 
PR interval irregular 
MEDICAL HISTORY 
• 2009 - Neurocirculatory dystonia  
• 2015 - Arterial hypertension 2nd stage 1st grade (max BP - 147/97 
mmHg) 
• 2016 - AV block second degree (Mobitz II)  
• 2017 - complete AV block  
PATIENT’S PREVIOUS TREATMENT 
• Ramipril 2.5 mg ones daily at evening 
 
ANAMNESIS VITAE 
• Married 
• None smoker 
• Denies alcohol consumption 
• Denies DM, tuberculosis, malaria, viral hepatitis, sexual transmitted 
diseases and AIDS 
• Allergic/Immunologic: denies urticaria, hay fever, persistent 
infections, HIV exposure  
• No family history of any endocrine disorder or cardiac disorder 
 
 
 
OBJECTIVE STATE 1.1 
• The general condition is satisfactory, consciousness is clear 
• Emotionally stable, optimistic mood 
• Hyperstenic, height = 168 cm, body weight = 100 kg, BMI=37.3 kg/m2  (obese) 
• Temperature – 36,7 C 
• Skin, visible mucous membranes are pale pink and clean 
• Mucous membranes are pale and wet 
• Tongue - clear and wet 
• Peripheral lymph nodes are not palpable 
• The thyroid is not palpable 
• Signs of eyelid retraction, periorbital edema, proptosis are absent 
• Joints are normal, active and passive movements are not painless 
 
OBJECTIVE STATE 1.2 
RESPIRATORY SYSTEM 
• Inspection: normal respiratory effort with no use of accessory muscles 
• Palpation: normal tactile fremitus 
• Auscultation: vesicular breathing, no added sounds   
OBJECTIVE STATE 1.3 
CARDIOVASCULARY SYSTEM 
• Palpation: no jugular vein distention, no carotid or abdominal bruits; 
no enlargement of abdominal aorta. Carotid, radial, posterior tibialis, 
and pedal pulses 2+ symmetric, no edema, HR=35 bpm 
• Percussion: heart borders extended to the left on 1,5 cm of 
midclavicular line  
• Auscultation: regular. S1, S2, normal rhythm, no murmur, rub, or 
gallop; no thrill or palpable murmurs. 
• Blood Pressure left hand = 145/100 mmHg (on the background of 
antihypertensive therapy), Blood Pressure of right hand = 
140/95mmHg 
 
OBJECTIVE STATE 1.4 
DIGESTIVE SYSTEM 
Abdomen is soft, painless, symmetrical, no discrepancies of the 
abdominal muscles, no visible peristalsis  
Liver edge is smooth, painless, palpated 0.5 cm below the costal arch  
Spleen and pancreas are not palpable 
OBJECTIVE STATE 1.5  
UROGENITAL SYSTEM 
• Pasternatsky sign: negative, no dysuria, no incontinence, 
• No polyuria 
• No nocturia, no urgency  
• No hematuria, no reduced flow, dribbling 
OBJECTIVE STATE 1.6 
SEXYAL SYSTEM 
• Menopause during 1 year 
OBJECTIVE STATE 1.7 
NERVOUS AND ENDOCRINE SYSTEM 
• Alert and oriented to person, place, and time. Able to communicate 
well. Cranial nerves 2-12 grossly intact. 5/5 strength in all extremities 
bilaterally. Sensation intact in all extremities. Normal gait.  
 

RESEARCH PLAN 
  Instrumental investigations: 
• ECG 
• EchoCG 
Laboratory investigations: 
• Complete blood test 
 • General urine test 
 • Biochemical blood test (Liver and renal function tests) 
 • Blood lipid spectrum 
 • Blood glucose level (Hb A1c) 
 
 
ECG: 2 DAYS AFTER PACING 09/09/17 
 
 
 
 
 
 
 
 
 
Conclusion: complete AV block, sinus atrial rhythm, PR interval irregular, RR>PP. ESPRITE DDD pacemaker: 
There is 100% ventricular capture — a QRS complex follows each ventricular pacing spike; no atrial pacing 
spikes are seen; HR-65bpm, stimulation threshold-0,75V, impedance-350Om 
 
ECHOCARDIOGRAPHY 06/09/17 
Name Result Normal 
Aorta 36.0 20-37 mm 
Aortic Valve 20.0 17-26 mm 
Left Atrium 37.0 To  38 mm 
Mitral Valve 33.0   26-35 mm 
End diastolic  velocity 120 50-180 cm/s 
End systolic volume 50 35-55 mm 
Left ventricular 13.5 6-11 mm 
Ejection fraction 65 55-78 % 
Left ventricular amplitude 10 mm 7-13 mm 
Intraventricular septum 12 mm 6-11 mm 
Right atrial diameter 36.0 ≤ 45 mm 
Right Ventricle D.: 20 mm D.: 9-26 mm 
Conclusion: Left ventricular hypertrophy. Signs of increasing diastolic stiffness of the left 
ventricular wall 
 
COMPLETE BLOOD COUNT 07/09/17 
INDEX  RESULT  NORMAL RANGE 
HEMOGBLOBIN 136 F 120-140 g/l 
ERYTHROCYTE S 4.6 F 3.9-4.7 T/L 
COLOR INDEX 1.01 0.85-1.15 
LEUKOCYTES 4,2 4-9 g/L 
ESR 14 F 2-15 mm/H 
THROMBOCYTES 310 180-320  g/L 
BAND NEUTROPHILS 3 1.0-6.0 % 
SEGMANTED NEUTROPHILS 51 47-72 % 
EOSINOPHILS  2 0.5-5.0 % 
BASOPHILS 1.0 0-1.0 % 
LYMPHOCYTES 30 19.0-37% 
MONOCYTE  13 3.0-11.0% 
HEMATOCRIT  41.6  F 36-42% 
CONCLUSION: Normal 
GENERAL URINE TEST 07/09/17 
CONCLUSION: Normal 
 
http://www.endmemo.com/medical/unitconvert/Dimethadione.php 
MEASURE RESULT NORMAL RANGE 
SPECIFIC GRAVITY 1.024 1,001-1,040 
REACTION 6.0 5,0-7,0 
PROTEIN 0.021 to 0.033 g / l 
GLUCOSE - Absent 
LEUCOCYTES 2-3 6-8 
EPITHELIUM TRANSITION Not detected Not detected 
BACTERIA Not detected Not detected 
BIOCHEMICAL ANALYSIS 07/09/17 
CONCLUSION: Normal 
INDEX RESULT NORMAL RANGE  
BILIRUBIN 10,3 1.7-21.0 μmol/L 
ASAT 37 < 37 U/L 
ALAT 22.3 < 41 U/L 
CREATININE  82 80-115 μmol/L 
FASTING GLUCOSE 5.62 4.2-6.1 μmol/L 
LIPID PROFILE 07/09/17  
CONCLUSION: IIa type of dyslipidemia  
INDEX RESULT  NORMAL RANGE  
TOTAL CHOLESTEROL  5.29 <5.2 
VLDL 0.31 <1.0 
LDL 3.75 <3.5 
HDL 1.22 >0.9 
TRIGLYCERIDE  0.70 <2.3 
ATHROGENIC COEFFICIENT  3.33 < 3,O 
BASIC CLINICAL SYNDROMES  
• Conduct disorder 
• Arterial Hypertension  
• Heart failure  
• Dyslipidemia  
• Obesity 
THE CLINICAL DIAGNOSIS 
ACCORDING TO CURRENT 
CLASSIFICATIONS 
DIFFERENCES BETWEEN AV HEART 
BLOCKS 
Type of AV block Rhythm P waves QRS complexes PR intervals 
1st degree Underlying rhythm is 
usually regular 
Present and normal; all 
the P waves are 
followed by a QRS 
complex 
Normal Longer than 0.20 
seconds and is constant 
2nd degree, type i Patterned irregularity Present and normal; not 
all the P waves are 
followed by a QRS 
complex 
Normal Progressively longer 
until a QRS complex is 
dropped; the cycle then 
begins again 
2nd degree, type II May be regular or 
irregular (depends on 
whether conduction 
ratio remains the same) 
Present and normal; not 
all the P waves are 
followed by a QRS 
complex 
Normal Constant for all 
conducted beats 
Comlete Atrial rhythm and 
ventricular rhytms are 
regular but not related 
to one another 
Present and normal; not 
related to the QRS 
complexes; appear to 
march through the QRS 
complexes 
Normal if escape focus 
is junctional and 
widened if escape focus 
is ventricular 
Not measurable  
https://www.slideshare.net/shubhendu3386/av-block-ecg-analysis  
CLASSIFICATION OF ARTERIAL 
HYPERTENSION 1.1 (clinical protocol Ministry of Health of 
Ukraine "Arterial hypertension "(Order No. 484), 2012) 
http://thepharmacystop.com/pharmacy/blood-pressure/  
CATEGORY SYSTOLIC DIASTOLIC 
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High normal 130-139 and/or 85-89 
Grade 1 hypertension 140-159 and/or 90-99 
Grade 2 hypertension 160-179 and/or 100-109 
Grade 3 hypertension >180 and/or >110 
CLASSIFICATION OF ARTERIAL 
HYPERTENSION 1.2 
STAGE THE DEGREE OF TARGET ORGAN DAMAGE 
I Objective changes in the target organs are absent 
II There is objective evidence of target organ damage without symptoms with their hand or 
dysfunction: 
Left ventricular hypertrophy (on ECG, ultrasound, Ro) 
Generalized narrowing of retinal arteries 
Microalbuminuria and/or a small increase in serum creatinine (in m. - 115 - 133 mmol/L in f. - 
107 - 124 mmol/l) 
Carotid artery disease - a thickening of the intima-media > 0.9 mm or the presence of 
atherosclerotic plaques 
III There is objective evidence of target organ damage with symptoms from their side and impaired 
heart - myocardial infarction, heart failure II A - III stage; brain - stroke, transient ischemic 
attack, acute hypertensive encephalopathy, vascular dementia; fundus - hemorrhage and retinal 
exudates with papilledema the optic nerve or without; kidney - concentration of plasma 
creatinine in m. > 133 umol/L, in f.. > 124; vessels - dissecting aortic aneurysm; peripheral 
arterial occlusion 
http://cardiopractic.com.ua/osnovnoj-material/8_1_-arterialnaya-gipertenziya/8_2_-klassifikaciya-ag.html  
RISK FACTORS OF ARTERIAL 
HYPERTENSION 
http://praharajheart.com/acute-heart-attack-learn-about-heart-attack-treatments-in-kolkata/  
CARDIOVASCULAR RISK STRATIFICATION 
CHART WITH RECOMMENDED FOLLOW-UP 
FREQUENCY FOR EACH CATEGORY 
http://care.diabetesjournals.org/content/32/suppl_2/S284  
THE NEW YORK HEART ASSOCIATION 
(NYHA) CLASSIFICATION OF HEART FAILURE 
CLASSES OBJECTIVE ASSESSMENT 
Class I No limitation of physical activity 
Class II 
 
Slight limitation of physical activity in which ordinary physical activity leads to fatigue, 
palpitation, dyspnea, or anginal pain; the person is comfortable at rest  
Class III 
 
Marked limitation of physical activity in which less-than-ordinary activity results in fatigue, 
palpitation, dyspnea, or anginal pain; the person is comfortable at rest  
Class IV 
 
Inability to carry on any physical activity without discomfort but also symptoms of heart failure 
or the anginal syndrome even at rest, with increased discomfort if any physical activity is 
undertaken  
https://emedicine.medscape.com/article/2500037-overview  
AMERICAN COLLEGE OF CARDIOLOGY 
FOUNDATION/AMERICAN HEART ASSOCIATION 
(ACCF/AHA) HEART FAILURE STAGING SYSTEM 
STAGE DESCRIPTION  EXAMPLES 
A At high risk for heart failure but without structural 
heart disease or symptoms of heart failure 
Patients with coronary artery disease, 
hypertension, or diabetes mellitus without 
impaired left ventricular (LV) function, LV 
hypertrophy (LVH), or geometric chamber 
distortion 
B Structural heart disease but without signs/symptoms 
of heart failure 
Patients who are asymptomatic but who have 
LVH and/or impaired LV function 
C Structural heart disease with current or past symptoms 
of heart failure 
Patients with known structural heart disease 
and shortness of breath and fatigue, reduced 
exercise tolerance 
D Refractory heart failure requiring specialized 
interventions 
Patients who have marked symptoms at rest 
despite maximal medical therapy 
https://emedicine.medscape.com/article/2500037-overview  
DEFINITION OF HEART FAILURE WITH 
PRESERVED (HFpEF),MID-RANGE(HFPEF) AND 
REDUCED EJECTION FRACTION (HFrEF) 
https://archive.is/ICiuC  
BMI CLASSIFICATION OF 
OVERWEIGHT AND OBESITY  
CLASSIFICATION BMI CATEGORY (kg/m2) RISK OF DEVELOPING 
HEALH  PROBLEMS 
Underweight < 18.5 Increased 
Normal weight 18.5 – 24.9 Least 
Overweight 25.0 – 29.9 Increased 
Obese class I 30.0 – 34.9 High 
Obese class II 35.0 – 39.9 Very high 
Obese class III ≥ 40.0 Extremely high 
http://www.marsden-weighing.co.uk/index.php/bmi-calculator/  
LIPOPROTEIN PATTERNS 
(FREDRICKSON PHENOTYPES)  
Phenotype Elevated Lipoprotein Elevated Lipids 
I Chylomicrons  TGs 
IIa LDL Cholesterol 
IIb LDL,VLDL TGs and Cholesterol 
III VLDL., Chylomicrons reminant  TGs and Cholesterol 
IV VLDL TGs 
V Chylomicrons , VDL TGs and cholesterol  
http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorder/lipid-disorder/dyslipidemia    
COMPLETE DIAGNOSIS OF OUR 
PATIENT 
Main: 
Ischemic heart disease 
Condition after cardiac pacemaker implantation (DDDR) due to complete AV 
block 
Essential arterial hypertension IInd stage, 1st grade, hypertensive heart (LVH) 
Heart failure II B, II FC with preserved ejection fraction (EF – 65%) 
Dyslipidemia II a type (after Fredrickson) 
Moderate added total CV risk 
Co-morbidity: 
Obesity II degree 
TREATMENT 
• Life style modification  
• Medical intervention  
TREATMENT OF AV BLOCKS 
Block type Treatment 
1st degree None 
2nd degree (Mobitz type 1) None 
2nd degree (Mobitz type 2) 
 
Pacemaker 
Complete AV block Pacemaker 
https://emedicine.medscape.com/article/162007-treatment  
LIFESTYLE CHANGES 
https://www.aace.com/files/dm-guidelines-ccp.pdf 
PARAMETER TREATMENT GOAL 
Weight loss 
(for overweight and obese patients) 
Reduce by 5% to 10% 
Physical activity 150 min/week of moderate-intensity exercise (eg, 
brisk walking) plus flexibility and strength training 
Diet • Eat regular meals and snacks; avoid fasting to lose 
weight 
• Consume plant-based diet (high in fiber, low 
calories/glycemic index, and high in 
phytochemicals/antioxidants) 
• Understand Nutrition Facts Label information 
• Incorporate beliefs and culture into discussions 
• Use mild cooking techniques instead of high-heat 
cooking 
• Keep physician-patient discussions informal 
PHARMACOLOGICAL TREATMENT FOR 
STABLE FORMS OF IHD 
Indication Class Level 
General considerations     
Optimal medical treatment indicates at least one drug for angina/ischemia relief plus drug for event prevention I C 
It is recommended to educate patients about the disease, risk factors and treatment strategy I C 
It is indicated to review the patient’s response soon after starting therapy I C 
Angina/ischemia relief     
Short-acting nitrates are recommended I B 
First-line treatment is indicated with -blockers and/or calcium channel blockers to control heart rate and symptoms I A 
For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil or ranolazine, according to heart rate, blood 
pressure and tolerance 
IIa B 
For second-line treatment, trimetazidine may be considered IIb B 
According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients I C 
In asymptomatic patients with large areas of ischemia (>10%) -blockers should be considered IIa C 
In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and -blockers avoided IIa B 
Event prevention     
Low-dose aspirin daily is recommended in all SCAD patients I A 
Clopidogrel is indicated as an alternative in case of aspirin intolerance I B 
Statins are recommended in all SCAD patients I A 
It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes) I A 
https://www.cardiosmart.org/heart-conditions/guidelines/sihd  
BLOOD PRESSURE GOALS IN 
HYPERTENSIVE PATIENTS 
2013 ESH/ESC Guidelines for the management of arterial hypertension 
TREATMENT STRATEGIES AND CHOISE OF 
DGUGS IN HYPERTENSIVE PATIENTS 
2013 ESH/ESC Guidelines for the management of arterial hypertension 
SUMMARY OF RECOMMENDATIONS ON 
THERAPEUTIC STRATEGIES IN HYPERTENSIVE 
PATIENTS WITH HEART DISEASE  
Recommendations Clas
s 
Leve
l 
In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered IIa B 
In hypertensive patients with a recent myocardial infarction -blockers are recommended. In case of other CHD all 
antihypertensive agents can be used, but -blockers and calcium antagonists are to be preferred, for symptomatic reason (angina) 
I A 
Diuretics, -blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are 
recommended in patients with heart failure or severe LV dysfunction to reduce mortality and hospitalization 
I A 
In patients with heart failure and preserved EF, there is no evidence that antihypertensive therapy per se or any particular drug, is 
beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 
140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with 
diuretics, high heart rate with -blockers, etc.) should also be considered 
IIa C 
ACE inhibitors and angiotensin receptor blockers (and -blockers and mineralocorticoid receptor antagonists if heart failure 
coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation 
IIa C 
It is recommended that all patients with LVH receive antihypertensive agents I B 
In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be 
considered, i.e. ACE inhibitors, angiotensin receptor blockers and calcium antagonists 
IIa B 
2013 ESH/ESC Guidelines for the management of arterial hypertension 
2016 ESC GUIDELINES FOR THE DIAGNOSTIC 
AND TREATMENT OF ACUTE AND CHRONIC 
HEART FAILURE 
Recommendations Class Level 
Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life I A 
Treatment with statins is recommended in patients with or at high-risk of CAD whether or not they have LV 
systolic dysfunction, in order to prevent or delay the onset of HF and prolong life 
I A 
Counselling and treatment for smoking cessation and alcohol intake reduction is recommended for people who 
smoke or who consume excess alcohol in order to prevent or delay the onset of HF 
I C 
Treating other risk factors of HF (e.g. obesity, dysglycaemia) should be considered in order to prevent or delay 
the onset of HF  
II a C 
Empagliflozin should be considered in patients with type 2 diabetes in order to prevent or delay the onset of HF 
and prolong life 
II a B 
HEART FAILURE TREATMENT 
RECOMMENDATION FOR TREATMENT 
OF STAGE B HEART FAILURE 
 
MONITORING LIPIDS AND ENZYMES IN 
PATIENTS ON LIPID-LOWERING THERAPY 
HEALTH CARE FACILITY TREATMENT  
 Control pacemaker parameters after 1, 6 months and 1 year 
Therapeutic drugs:  
Cardiomagnyl: 75 mg once daily in the evening 
Telstartan: 40 mg once daily in the morning 
Artovastatin: 40 mg once daily in the evening  
 Control of the lipid profile and liver function test after 3 months 

